For the first time in decades, the federal government is moving - however cautiously - toward treating marijuana as something other than a substance with no accepted medical value. An order issued by Acting Attorney General Todd Blanche on April 23 directed the Department of Justice and the Drug Enforcement Administration to begin reclassifying medical-grade marijuana from Schedule I to Schedule III under the Controlled Substances Act, a shift that places it alongside codeine and ketamine rather than heroin and LSD. For Hawai'i state Rep. David Tarnas, who has spent years pushing recreational cannabis legalization through a legislature that hasn't been ready to move, the development represents something rare in drug policy: actual federal momentum.
What the Order Actually Does - and Doesn't Do
The distinction matters here. Blanche's order covers two specific categories: FDA-approved drug products containing marijuana, and medicinal marijuana products regulated under a qualifying state-issued license. It does not, on its own, legalize recreational use, change state law, or automatically alter how existing medical cannabis programs operate. Hawai'i's Department of Health confirmed as much in a statement, noting that there are "no immediate changes to state law or program operations" while the implementation process is still being worked out.
The order also initiates an expedited administrative hearing process - set to begin June 29, with notice published in the Federal Register - to consider the broader rescheduling of all marijuana from Schedule I to Schedule III. That hearing is the more consequential proceeding. It is the mechanism through which full reclassification could happen, and its outcome is not predetermined. There are still regulatory hurdles, public comment periods, and the long institutional memory of federal drug enforcement to contend with.
What's striking here is the legal basis Blanche invoked: his authority to reschedule drugs to fulfill U.S. obligations under the Single Convention on Narcotic Drugs, a 1961 international treaty. That's a narrow, procedural hook - but it's a real one, and it bypasses some of the more protracted congressional pathways that have stalled rescheduling efforts before.
Hawai'i's Long Wait on Recreational Legalization
Hawai'i has a complicated relationship with cannabis reform. The state was, in 2000, the first in the country to legalize medical marijuana through a legislative vote rather than a ballot initiative - a distinction worth noting, because it meant elected officials put their names on it rather than deferring to the electorate. That took political will. Recreational legalization has demanded more of it than the legislature has been willing to supply.
Tarnas, who represents North and South Kohala on the Big Island, has introduced adult-use legalization bills for several consecutive sessions. None have advanced. In 2019, the state decriminalized possession of three grams or less - former Gov. David Ige allowed the bill to become law without signing it, a gesture that speaks volumes about the political comfort level at the time. That's where things have largely sat.
The industry and broader community, Tarnas acknowledged, remain uncertain about how federal rescheduling will interact with the existing medical framework. That's a reasonable uncertainty. Schedule III status would ease restrictions on research, potentially allow cannabis businesses to deduct ordinary business expenses under federal tax law - something Schedule I classification currently prohibits - and signal to insurers, banks, and institutional investors that the regulatory ground is shifting. But "shifting" is not the same as "settled."
The Research Argument, Finally Given Room
One of the more durable arguments for rescheduling has always been scientific rather than political: Schedule I classification makes it extraordinarily difficult to conduct controlled clinical research on a substance that tens of millions of Americans already use. The scheduling system requires researchers to navigate layers of DEA licensing and federal oversight that don't apply to Schedule II or III substances, creating a situation where cocaine - Schedule II - is technically easier to study than marijuana.
Blanche's order explicitly frames rescheduling as a research enabler, arguing it allows for better evaluation of safety and efficacy, ultimately giving patients better care and physicians more reliable data. CBD, the non-psychoactive cannabis compound addressed in Trump's December executive order - which preceded Thursday's broader action - has already demonstrated clinical utility in treating certain forms of epilepsy, and is used widely for anxiety, pain, and sleep. The research pathway for other compounds in the cannabis plant has been far more obstructed. Schedule III status would attenuate some of that friction.
What Comes Next, and Why It Isn't Simple
The June 29 hearing will determine whether the broader rescheduling holds up through administrative review. DEA Administrator Terry Cole framed the process in law enforcement terms - consistency, oversight, cartel suppression - which is a reminder that this is not a legalization order. The federal prohibition on recreational marijuana use remains intact. The illicit market, which has operated alongside legal state programs for years, remains a DEA priority.
For states like Hawai'i, the practical question is downstream: if federal rescheduling clarifies the relationship between state medical programs and federal law, does it also loosen the political resistance to recreational legalization at the state level? Tarnas thinks it might. He said he is "hopeful" and monitoring closely, which is a careful way of saying he's watching to see whether Washington finally gives state legislators the cover they've been waiting for.
To put it plainly: federal drug policy rarely moves fast, and when it does, the implementation rarely matches the announcement. But the direction here is clear, and that alone is something Hawai'i's cannabis advocates haven't had in a while.
